January 20, 2012: Takeda Pharmaceutical Company Limited has announced strategic measures ‘to better align its global workforce and consolidate site operations’ in order to integrate legacy Nycomed operations and adapt to changing market conditions. The company said the measures support both the execution of its strategy and its integration targets announced last year. Takeda said it would also bring ‘further efficiencies’ to the organisation to sustain medium- and long-term growth targets starting in fiscal 2015. These activities include the alignment of Nycomed’s former operation structures and processes with Takeda’s global headquarters in Japan and with the company’s newly established departments of the Chief Commercial Officer, headquartered in Zurich, Switzerland, and of the Chief Medical & Scientific Officer, headquartered in Deerfield, Illinois, USA, as well as with the company’s expanded affiliate network worldwide. The company said it would secure a sustainable future by maximising the synergies of the steady integration of Takeda and Nycomed, such as the sales expansion of Takeda’s product pipeline utilising Nycomed’s sales platforms in Europe and emerging countries.
Takeda also plans to consolidate its R&D sites to ensure ongoing support for all marketed products and support development and global registration of new products. The company will invest strongly in R&D focused on core therapeutic areas, while effectively deploying both internal and external resources ‘maximising efficiency, driving standardisation, optimising resource utilisation and driving productivity.’ This will entail the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of the workforce in the USA, primarily within Takeda Pharmaceuticals North America. The company plans a reduction of the global Takeda global workforce of about 2,800 positions (2,100 mainly in Europe and 700 in the USA) by the end of fiscal 2015, including positions in R&D, operations and commercial activities.
To meet the needs of the market, Takeda will also shift from a product portfolio centred on mature, high-selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
The financial impact of the plan within fiscal 2011 ending March 2012 is estimated at a reduction in income of Yen 35 billion (about $456 million). The revised forecast of Takeda’s consolidated financial statements, including these strategic measures and other factors, will be disclosed upon the company’s fiscal 2011 3Q earnings announcement scheduled for February 1, 2012.
- RSS Feed
